Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 362 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is W  [Clear All Filters]
2026
Tsai C-Y, Xie M, Cristaldo M, Peluso GR, Woo J, Nuritdinov F, Odjourian NM, Dougher M, Antilus-Sainte R, Kreutzfeldt KM et al..  2026.  BCG vaccination with adjunctive APRIL immunotherapy reduces tuberculosis relapse in mice.. J Infect Dis.
Seshadri C, Flynn JAL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, Mwandumba HC, Jambo KC, Hoft DF, Rubin EJ et al..  2026.  Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.. Lancet Microbe. :101278.
Liu Q, Engelhart CA, Wallach JB, Ge P, Wong T-Y, Orimoloye MO, Rodriguez S, Jayasinghe YP, Ronning DR, Dartois V et al..  2026.  Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.. J Med Chem.
Liu Q, Engelhart CA, Wallach JB, Ge P, Wong T-Y, Orimoloye MO, Rodriguez S, Jayasinghe YP, Ronning DR, Dartois V et al..  2026.  Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.. J Med Chem.
Warrier T, Martinez-Hoyos M, de Francisco EPorras, Lenaerts AJ, Gruppo V, Robertson GT, Li K, Aubé J, Bonnet I, Jiang X et al..  2026.  Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.. ACS Infect Dis.
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Prajapati SK, Dong JX, Morahan BJ, Dotrang T, Barbeau MC, Williams AE, Hupalo D, Wilkerson MD, Dalgard CL, Kafsack BFC et al..  2026.  A single valine to leucine switch disrupts Plasmodium falciparum AP2-G DNA binding and reveals GDV1's role in ap2-g activation.. Nat Commun.
Prajapati SK, Dong JX, Morahan BJ, Dotrang T, Barbeau MC, Williams AE, Hupalo D, Wilkerson MD, Dalgard CL, Kafsack BFC et al..  2026.  A single valine to leucine switch disrupts Plasmodium falciparum AP2-G DNA binding and reveals GDV1's role in ap2-g activation.. Nat Commun.
Prajapati SK, Dong JX, Morahan BJ, Dotrang T, Barbeau MC, Williams AE, Hupalo D, Wilkerson MD, Dalgard CL, Kafsack BFC et al..  2026.  A single valine to leucine switch disrupts Plasmodium falciparum AP2-G DNA binding and reveals GDV1's role in ap2-g activation.. Nat Commun.
Theriault ME, Wong AI, DeJesus MA, Pisu D, Lee BNae Rin, Kirukubar G, Li S, Wallach JB, Schnappinger D, Lê-Bury G et al..  2026.  Utilization of a CRISPRi-based ex vivo challenge model to reveal temporally dependent gene essentiality in intracellular Mycobacterium tuberculosis.. mBio. :e0061026.
Theriault ME, Wong AI, DeJesus MA, Pisu D, Lee BNae Rin, Kirukubar G, Li S, Wallach JB, Schnappinger D, Lê-Bury G et al..  2026.  Utilization of a CRISPRi-based ex vivo challenge model to reveal temporally dependent gene essentiality in intracellular Mycobacterium tuberculosis.. mBio. :e0061026.
2025
Wu X, Huang S, Gao J, Huang S, Chen L, Zhao Z, Pu R, Ma X, Liu X, He W et al..  2025.  AKR1B10 dictates c-Myc stability to suppress colorectal cancer metastasis via PP2A nitration.. Sci Adv. 11(34):eadv6937.
Smith AA, Su H, Wallach J, Liu Y, Maiello P, H Borish J, Winchell C, Simonson AW, Lin PLing, Rodgers M et al..  2025.  A BCG kill switch strain protects against Mycobacterium tuberculosis in mice and non-human primates with improved safety and immunogenicity.. Nat Microbiol. 10(2):468-481.
Smith AA, Su H, Wallach J, Liu Y, Maiello P, H Borish J, Winchell C, Simonson AW, Lin PLing, Rodgers M et al..  2025.  A BCG kill switch strain protects against Mycobacterium tuberculosis in mice and non-human primates with improved safety and immunogenicity.. Nat Microbiol. 10(2):468-481.
J Vandana J, Zhu J, Giani AMaria, Zhang T, Lacko LA, Leng D, D Taylor L, Lee BN, Han Z, Jiao T et al..  2025.  ChemPerturb-seq screen identifies a small molecule cocktail enhancing human beta cell survival after subcutaneous transplantation.. Cell Stem Cell. 32(8):1299-1307.e8.
Davis SH, Mathieson M, Buchanan KI, Dawson A, Smith A, Cocco M, Tamaki FK, Post JM, Baragaña B, Jansen C et al..  2025.  Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.. J Med Chem. 68(15):16459-16482.
Davis SH, Mathieson M, Buchanan KI, Dawson A, Smith A, Cocco M, Tamaki FK, Post JM, Baragaña B, Jansen C et al..  2025.  Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.. J Med Chem. 68(15):16459-16482.
Ohara K, Assaad MAl, McNulty SN, Alnajar H, Sboner A, Wilkes DC, He F, Xiang JZhaoying, Mathew S, Elemento O et al..  2025.  Detection of rare and novel gene fusions in patients with diffuse glioma: An institutional retrospective study.. J Neuropathol Exp Neurol. 84(3):269-271.
Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al..  2025.  Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.
Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al..  2025.  Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.
Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al..  2025.  Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.